PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 5, 2026Cancer Research0 citations

Abstract 6673: MERFISH 2.0 enables high-sensitivity, customizable spatial transcriptomics for resolving immune and tumor programs in human cancers

View Full Paper
RCRenchao ChenBWBin WangBYBing Yang

Key Points

  • To improve the detection of transcripts in human tumors using MERFISH 2.0 and explore its applications in spatial transcriptomics.
  • Applied MERFISH 2.0 technology on human tumor specimens using an 815-gene immune-oncology panel.
  • Integrated custom genes to enhance focus on specific biological processes.
  • Utilized MERSCOPE® Ultra™ slides for high-resolution spatial mapping.
  • Achieved significantly higher transcript detection efficiency in tumor tissues.
  • Generated spatial maps that visualize immune cell distribution and organization within the tumor microenvironment.
  • Expanded the usability of MERFISH 2.0 for deciphering molecular features influencing tumor behavior.

Abstract

Abstract High-plex, imaging-based spatial transcriptomics with single-cell resolution has substantially advanced our understanding of how heterogeneous tumor ecosystems shape immune architecture and function, target expression, and cell-cell interface dynamics within the human tumor microenvironment (TME). By measuring gene expression directly in intact human tissues, spatial transcriptomics provides detailed insights into immune-cell identity, spatial organization, and molecular programs that govern antitumor activity or immune suppression. Resolving transcripts in situ enables precise delineation of immune-cell states, spatial interactions, and regulatory circuits underlying antitumor responses and context-dependent cellular phenotypes. A key limitation of current spatial transcriptomics approaches is the ability to sensitively detect transcripts across complex and heterogeneous human tumors, particularly when studies require focused interrogation of specific pathways or cellular programs. MERFISH 2.0 overcomes these constraints with an enhanced chemistry and streamlined sample-processing workflow that delivers substantially higher transcript detection efficiency in both frozen and FFPE tissue, enabling robust profiling of panels up to 1,000 genes. Building on these improvements in sensitivity and workflow performance, MERFISH 2.0 also provides the flexibility to add up to 100 custom genes to Pre-designed Panels (PdP), enabling researchers to tailor experiments to specific hypotheses, tumor-intrinsic biology, or emerging clinical signatures. In this study, MERFISH 2.0 was applied to human tumor specimens using an 815-gene PdP with an immune-oncology focus, supplemented with custom gene content selected to capture key biological processes across diverse tumor types and disease stages. Implementation on MERSCOPE® Ultra™ slides generated high-resolution spatial maps that resolved the distribution of specific cell populations, the localization of surface and intracellular markers of interest, and the complex organization of immune infiltrates, stromal architecture, and tumor-intrinsic transcriptional programs within intact tissue environments. The ability to augment MERFISH 2.0 panels with tailored gene sets further expands its utility for dissecting molecular features and spatial patterns of the TME that influence pathway engagement and functional activity. By integrating enhanced sensitivity with customizable panel design, MERFISH 2.0 provides a powerful platform for resolving spatial determinants of immune function and tumor behavior, supporting mechanistic discovery and informing the development of next-generation precision medicine strategies. Citation Format: Renchao Chen, Bin Wang, Bing Yang, Manisha Ray, Justin He, Timothy Wiggin, Lizi Maziashvili, Alexander Genshaft, Peter Reinhold, Angela Vasaturo, Jiang He. MERFISH 2.0 enables high-sensitivity, customizable spatial transcriptomics for resolving immune and tumor programs in human cancers abstract. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6673.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd8ea79560c99a0a3a69https://doi.org/10.1158/1538-7445.am2026-6673
Ask AI
Helpful
Bookmark
Share
View Full Paper